Averitas Pharma INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$3.5Mgeneral payments (2019-2025)
$0.00research payments (2019-2025)
16,996clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Mark Coleman | Pikesville, MD | Interventional Pain Medicine | $182,089.46 |
| Adam Teichman | Allentown, PA | Foot & Ankle Surgery | $177,360.24 |
| Alaa Abd-Elsayed | Madison, WI | Pain Medicine | $154,387.39 |
| Michael King | Nashville, TN | Podiatrist | $153,354.08 |
| Maged Guirguis | New Orleans, LA | Interventional Pain Medicine | $145,727.20 |
| Gary Graf | Topeka, KS | Nurse Practitioner | $145,069.98 |
| David Reece | Bethesda, MD | Physical Medicine & Rehabilitation | $129,095.70 |
| Waleed El-Feky | Dallas, TX | Neurology (Psychiatry & Neurology) | $113,923.34 |
| Zohra Hussaini | Kansas City, KS | Family | $104,118.78 |
| James North | Winston Salem, NC | Pain Medicine | $102,182.04 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.